{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:23:24Z","timestamp":1787167404350,"version":"build-2736575974"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"2","funder":[{"DOI":"10.13039\/100000865","name":"Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100021177","name":"CDC Foundation","doi-asserted-by":"publisher","award":["INV-004550"],"award-info":[{"award-number":["INV-004550"]}],"id":[{"id":"10.13039\/100021177","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009054","name":"PEPFAR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Evidence shows that isoniazid preventive therapy (IPT) reduces tuberculosis (TB) incidence among people with human immunodeficiency virus (HIV) with additive benefit beyond antiretroviral therapy alone, but its effectiveness in settings with high multidrug-resistant TB (MDR-TB) burden is unclear. We assessed the relationship between IPT and TB incidence among people with HIV (PWH) in Ukraine, a high-burden (32.6%) MDR-TB setting, and whether its effectiveness is maintained among virologically suppressed persons.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed national surveillance data for HIV and TB collected between 2018 and 2022. Complete IPT (n = 40 733) was defined as receipt of \u2265146 days of therapy and no IPT (n = 91 022) as &amp;lt;28 days of therapy. We modeled TB incidence and death using Poisson regression adjusting for covariates related to receipt of IPT and TB incidence. The secondary outcome was multidrug resistance, and sensitivity analyses explored the influence of virologic suppression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 131 755 PWH who met inclusion criteria, 9089 (5.5%) died. Unadjusted TB incidence was 1.91 cases per 100 person-years in the No IPT group and 1.01 cases per 100 person-years in the Complete IPT group (adjusted incidence rate ratio [aIRR], 1.99). MDR-TB occurred in 29.1% and 30.7% of TB cases in the Complete and No IPT groups, respectively. Among virologically suppressed PWH, persons with no IPT had a higher TB incidence (aIRR, 1.38) than those who completed IPT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Completing IPT as part of a public health intervention can significantly reduce TB incidence among PWH, even in settings with high-burden MDR-TB and among the virologically suppressed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciaf069","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T16:23:17Z","timestamp":1742228597000},"page":"314-321","source":"Crossref","is-referenced-by-count":4,"title":["Lower Tuberculosis Incidence Among People With HIV Who Completed Isoniazid Preventive Therapy in Ukraine, a High-Burden Multidrug-Resistant Tuberculosis Setting: A Retrospective Cohort Study"],"prefix":"10.1093","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7616-3303","authenticated-orcid":false,"given":"Olutomi","family":"Sodeke","sequence":"first","affiliation":[{"name":"Division of Global HIV and Tuberculosis, Global Health Center, Centers for Disease Control and Prevention , Atlanta, Georgia ,","place":["USA"]},{"name":"Epidemic Intelligence Service, Global Health Center, Centers for Disease Control and Prevention , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6069-0857","authenticated-orcid":false,"given":"N Sarita","family":"Shah","sequence":"additional","affiliation":[{"name":"Division of Global HIV and Tuberculosis, Global Health Center, Centers for Disease Control and Prevention , Atlanta, Georgia ,","place":["USA"]},{"name":"Department of Epidemiology, Rollins School of Public Health, Emory University , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0003-6236","authenticated-orcid":false,"given":"Sherri","family":"Pals","sequence":"additional","affiliation":[{"name":"Division of Global HIV and Tuberculosis, Global Health Center, Centers for Disease Control and Prevention , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serhii","family":"Riabokon","sequence":"additional","affiliation":[{"name":"Public Health Center of Ukraine, Ministry of Health , Kyiv, Kyiv Oblast ,","place":["Ukraine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olena","family":"Samsonova","sequence":"additional","affiliation":[{"name":"Public Health Center of Ukraine, Ministry of Health , Kyiv, Kyiv Oblast ,","place":["Ukraine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadimatu","family":"Mishara","sequence":"additional","affiliation":[{"name":"Infectious Disease Program, National Foundation for the Centers for Disease Control and Prevention , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Doan","sequence":"additional","affiliation":[{"name":"Division of Global HIV and Tuberculosis, Global Health Center, Centers for Disease Control and Prevention Ukraine , Kyiv, Kyiv Oblast ,","place":["Ukraine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larysa","family":"Hetman","sequence":"additional","affiliation":[{"name":"Public Health Center of Ukraine, Ministry of Health , Kyiv, Kyiv Oblast ,","place":["Ukraine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezra","family":"Barzilay","sequence":"additional","affiliation":[{"name":"Division of Global HIV and Tuberculosis, Global Health Center, Centers for Disease Control and Prevention Ukraine , Kyiv, Kyiv Oblast ,","place":["Ukraine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nataliya","family":"Podolchak","sequence":"additional","affiliation":[{"name":"Division of Global HIV and Tuberculosis, Global Health Center, Centers for Disease Control and Prevention Ukraine , Kyiv, Kyiv Oblast ,","place":["Ukraine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Da Silva","sequence":"additional","affiliation":[{"name":"Division of Global HIV and Tuberculosis, Global Health Center, Centers for Disease Control and Prevention , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,18]]},"reference":[{"key":"2025091917003445000_ciaf069-B1","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/j.ijid.2020.03.011","article-title":"Historical review of studies on the effect of treating latent tuberculosis","volume":"92","author":"M\u00f8lhave","year":"2020","journal-title":"Int J Infect Dis"},{"key":"2025091917003445000_ciaf069-B2","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJMoa1507198","article-title":"A trial of early antiretrovirals and isoniazid preventive therapy in Africa","volume":"373","author":"TEMPRANO ANRS 12136 Study Group","year":"2015","journal-title":"N Engl J Med"},{"key":"2025091917003445000_ciaf069-B3","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa1806808","article-title":"One month of rifapentine plus isoniazid to prevent HIV-related tuberculosis","volume":"380","author":"Swindells","year":"2019","journal-title":"N Engl J Med"},{"key":"2025091917003445000_ciaf069-B4","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1016\/S2352-3018(20)30299-X","article-title":"Isoniazid preventive therapy plus antiretroviral therapy for the prevention of tuberculosis: a systematic review and meta-analysis of individual participant data","volume":"8","author":"Ross","year":"2021","journal-title":"Lancet HIV"},{"key":"2025091917003445000_ciaf069-B5","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","article-title":"Three months of rifapentine and isoniazid for latent tuberculosis infection","volume":"365","author":"Sterling","year":"2011","journal-title":"N Engl J Med"},{"key":"2025091917003445000_ciaf069-B6","volume-title":"President\u2019s Emergency Plan for AIDS Relief TB commitment implementation strategy","author":"Advancing TB Case Detection and Mortality Reduction Among PLHIV","year":"2023"},{"key":"2025091917003445000_ciaf069-B7","volume-title":"WHO consolidated guidelines on tuberculosis. Module 1: prevention\u2014tuberculosis preventive treatment","author":"World Health Organization","year":"2020"},{"key":"2025091917003445000_ciaf069-B8","doi-asserted-by":"crossref","first-page":"912","DOI":"10.5588\/ijtld.13.0028","article-title":"Treatment for LTBI in contacts of MDR-TB patients, Federated States of Micronesia, 2009\u20132012","volume":"18","author":"Bamrah","year":"2014","journal-title":"Int J Tuberc Lung Dis"},{"key":"2025091917003445000_ciaf069-B9","doi-asserted-by":"crossref","first-page":"805","DOI":"10.3201\/eid2703.203916","article-title":"Effectiveness of preventive therapy for persons exposed at home to drug-resistant tuberculosis, Karachi, Pakistan","volume":"27","author":"Malik","year":"2021","journal-title":"Emerg Infect Dis"},{"key":"2025091917003445000_ciaf069-B10","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.3390\/pathogens11101189","article-title":"Preventive therapy for contacts of drug-resistant tuberculosis","volume":"11","author":"Kherabi","year":"2022","journal-title":"Pathogens"},{"key":"2025091917003445000_ciaf069-B11","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1164\/rccm.201908-1576OC","article-title":"Isoniazid preventive therapy in contacts of multidrug-resistant tuberculosis","volume":"202","author":"Huang","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2025091917003445000_ciaf069-B12","volume-title":"WHO global lists of high burden countries for TB, multidrug\/rifampicin-resistant TB (MDR\/RR-TB) and TB\/HIV, 2021\u20132025","author":"World Health Organization","year":"2021"},{"key":"2025091917003445000_ciaf069-B13","doi-asserted-by":"crossref","first-page":"197","DOI":"10.5588\/ijtld.17.0254","article-title":"Alarming levels of multidrug-resistant tuberculosis in Ukraine: results from the first national survey","volume":"22","author":"Pavlenko","year":"2018","journal-title":"Int J Tuberc Lung Dis"},{"key":"2025091917003445000_ciaf069-B14","article-title":"Ukraine","author":"Joint United Nations Programme on HIV\/AIDS","year":"2021"},{"key":"2025091917003445000_ciaf069-B15","volume-title":"Global tuberculosis report 2022","author":"World Health Organization","year":"2022"},{"key":"2025091917003445000_ciaf069-B16","first-page":"80","article-title":"The medical information system \u201cHIV-infection in Ukraine\u201d: development and implementation","volume":"5","author":"Kovtun","year":"2019","journal-title":"Public Health Panorama"},{"key":"2025091917003445000_ciaf069-B17","doi-asserted-by":"crossref","first-page":"00002-2017","DOI":"10.1183\/23120541.00002-2017","article-title":"User experience analysis of e-TB Manager, a nationwide electronic tuberculosis recording and reporting system in Ukraine","volume":"3","author":"Konduri","year":"2017","journal-title":"ERJ Open Res"},{"key":"2025091917003445000_ciaf069-B18","article-title":"Tuberculosis","author":"Joint United Nations Programme on HIV\/AIDS","year":"2023"},{"key":"2025091917003445000_ciaf069-B19","volume-title":"WHO consolidated guidelines on tuberculosis. Module 2: screening\u2014systematic screening for tuberculosis disease","author":"World Health Organization","year":"2021"},{"key":"2025091917003445000_ciaf069-B20","doi-asserted-by":"crossref","first-page":"203","DOI":"10.5588\/ijtld.11.0445","article-title":"Global isoniazid resistance patterns in rifampin-resistant and rifampin-susceptible tuberculosis","volume":"16","author":"Smith","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"key":"2025091917003445000_ciaf069-B21","volume-title":"WHO consolidated guidelines on tuberculosis. Module 3: diagnosis\u2014rapid diagnostics for tuberculosis detection. 3rd ed","author":"World Health Organization","year":"2024"},{"key":"2025091917003445000_ciaf069-B22","volume-title":"WHO operational handbook on tuberculosis. Module 4: treatment\u2014drug-resistant tuberculosis treatment, 2022 update","author":"World Health Organization","year":"2022"},{"key":"2025091917003445000_ciaf069-B23","article-title":"A5300B\/I2003B: protecting households on exposure to newly diagnosed index multidrug-resistant tuberculosis patients (PHOENIx MDR-TB)","author":"AIDS Clinical Trials Group IMPAACT Network","year":"2020"},{"key":"2025091917003445000_ciaf069-B24","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1186\/s13063-018-3070-0","article-title":"Levofloxacin versus placebo for the prevention of tuberculosis disease in child contacts of multidrug-resistant tuberculosis: study protocol for a phase III cluster randomised controlled trial (TB-CHAMP)","volume":"19","author":"Seddon","year":"2018","journal-title":"Trials"},{"key":"2025091917003445000_ciaf069-B25","doi-asserted-by":"crossref","first-page":"e033945","DOI":"10.1136\/bmjopen-2019-033945","article-title":"Levofloxacin versus placebo for the treatment of latent tuberculosis among contacts of patients with multidrug-resistant tuberculosis (the VQUIN MDR trial): a protocol for a randomised controlled trial","volume":"10","author":"Fox","year":"2020","journal-title":"BMJ Open"},{"key":"2025091917003445000_ciaf069-B26","doi-asserted-by":"crossref","first-page":"4599","DOI":"10.1111\/bph.14867","article-title":"Isoniazid and host immune system interactions: a proposal for a novel comprehensive mode of action","volume":"176","author":"Khan","year":"2019","journal-title":"Br J Pharmacol"},{"key":"2025091917003445000_ciaf069-B27","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1128\/AAC.05486-11","article-title":"A novel metabolite of antituberculosis therapy demonstrates host activation of isoniazid and formation of the isoniazid-NAD+ adduct","volume":"56","author":"Mahapatra","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2025091917003445000_ciaf069-B28","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.abb.2019.01.004","article-title":"Isoniazid induces a monocytic-like phenotype in HL-60 cells","volume":"664","author":"Babu","year":"2019","journal-title":"Arch Biochem Biophys"},{"key":"2025091917003445000_ciaf069-B29","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/joim.12256","article-title":"Inflammation and tuberculosis: host-directed therapies","volume":"277","author":"Zumla","year":"2015","journal-title":"J Intern Med"},{"key":"2025091917003445000_ciaf069-B30","doi-asserted-by":"crossref","first-page":"102286","DOI":"10.1016\/j.tube.2022.102286","article-title":"Genetic mutations underlying isoniazid-resistant Mycobacterium tuberculosis in Khyber Pakhtunkhwa, Pakistan","volume":"138","author":"Khan","year":"2023","journal-title":"Tuberculosis (Edinb)"},{"key":"2025091917003445000_ciaf069-B31","doi-asserted-by":"crossref","first-page":"744","DOI":"10.3201\/eid1205.050681","article-title":"Isoniazid preventive therapy and risk for resistant tuberculosis","volume":"12","author":"Balcells","year":"2006","journal-title":"Emerg Infect Dis"},{"key":"2025091917003445000_ciaf069-B32","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1056\/NEJMoa2314325","article-title":"Levofloxacin for the prevention of multidrug-resistant tuberculosis in Vietnam","volume":"391","author":"Fox","year":"2024","journal-title":"N Engl J Med"},{"key":"2025091917003445000_ciaf069-B33","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1056\/NEJMoa2314318","article-title":"Levofloxacin preventive treatment in children exposed to MDR tuberculosis","volume":"391","author":"Hesseling","year":"2024","journal-title":"N Engl J Med"},{"key":"2025091917003445000_ciaf069-B34","doi-asserted-by":"crossref","first-page":"S644","DOI":"10.1093\/infdis\/jix354","article-title":"Drivers of tuberculosis transmission","volume":"216","author":"Mathema","year":"2017","journal-title":"J Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaf069\/62434987\/ciaf069.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/81\/2\/314\/62434987\/ciaf069.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/81\/2\/314\/62434987\/ciaf069.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T21:00:42Z","timestamp":1758315642000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/81\/2\/314\/8082945"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,18]]},"references-count":34,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,3,18]]},"published-print":{"date-parts":[[2025,9,16]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaf069","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8,15]]},"published":{"date-parts":[[2025,3,18]]}}}